Abstract: A composition consisting essentially of human leukocyte interferon and an antiviral surfactant, such as the non-ionic surfactant, nonylphenoxypolyethoxy ethanol, and a physiologically acceptable carrier therefor, has been found to be useful for the treatment of malignant and pre-malignant skin lesions and skin lesions associated with herpes zoster and psoriasis by topically administering or applying the composition to the affected skin area.

Abstract: Compositions containing a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF.alpha.), transforming growth factor-beta (TGF-.beta.), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) including cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and/or opsonic-alpha 2 surface binding glycoprotein in a suitable physiologically acceptable carrier are useful for the treatment of humans when topically and/or subcutaneously applied. These compositions might also usefully contain or have employed in association therewith an adjuvant to aid in the transdermal transport or transfer of the compositions, particularly the active components therein, through or across the skin.

Abstract: A composition containing an antiviral and an antitumor agent is useful when topically applied for the treatment of tumors and cancers, particularly for the treatment of viral or cancerous skin disorders and skin manifestations thereof. Interferon is usefully employed in these compositions in combination with the antitumor agent. Antitumor agents which are useful include interleukin, such as Interleukin II, tumor necrosis factor (TNF), target cell lysis factor (TCLF) and carcino-breaking factor (CBF). These compositions are especially usefully applied by topical application to the skin manifestation of the viral or cancerous skin disorder.

Abstract: A method for the cosmetic treatment of human skin, particularly facial skin, for the removal of materials from the surface and the sebaceous follicles is disclosed. The method comprises applying a layer of liquid polymerizable adhesive to the skin, then applying a pliable adhesive tape to cover the applied liquid adhesive and allowing the polymerization of said layer of polymerizable adhesive to take place and then removing the layer of polymerized adhesive from the skin by stripping the tape from the skin. In this treatment the materials on the surface of the skin and within the sebaceous follicles being attached to and removed with the layer of polymerized adhesive along with the tape. Alpha-cyanoacrylate is usefully employed as the polymerizable adhesive in this treatment.

Abstract: A composition for treating herpes simplex viral infections in humans is disclosed, comprising about 10.sup.2 to 10.sup.8 I.U. of human interferon, about 0.1% to 20% by weight of an antiviral surface active agent, and a physiologically acceptable carrier. Most preferably, the composition comprises about 10.sup.4 to 10.sup.6 I.U. of human leukocyte interferon, about 1% to 5% by weight of a nonionic surface active agent having at least one ether or amide linkage, and a physiologically acceptable carrier. A method for treating herpes simplex viral infections in humans is also disclosed, comprising topically administering an effective amount of said antiherpetic composition to the affected area. Most preferably, an effective amount of said antiherpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication.